Propel testing excellence with Mayo Clinic quality
Mayo Clinic Laboratories is a one-stop laboratory solution, offering commercial laboratories a vast testing menu, unparalleled customer service, and optimized processes. We work collaboratively with partners to assess their needs, providing the testing they need to expand into new areas and meet their business goals.
As the reference lab for Mayo Clinic, we’ve developed robust logistics and testing protocols applied uniformly for all specimens received, no matter their geographic origin. Whether you send us one test order or thousands, each sample receives the same treatment and level of care, ensuring superior results that help our partners better serve their clients.
“Our clients want personal experiences. They want someone to answer the phone. They want someone to provide answers when they're looking for results of a sample sent a couple days ago. and we deliver those answers.”
Angie Reese-Davis, director of operations, logistics, and specimen services, Mayo Clinic Laboratories
Our difference
News and updates
The latest
Mayo Clinic Laboratories is transforming diagnostics with innovations in 2025 that turned research into real-world solutions for better patient care.
Recognizing the powerful role genes can play in diagnosing illness and guiding treatment, the Division of Laboratory Genetics and Genomics at Mayo Clinic spearheaded a testing expansion, implementing and upgrading more than 60 advanced sequencing and biochemical assays in 2023 and planning for even more this year.
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' test panel provides comprehensive evaluation of patients with suspected monogenic early onset inflammatory bowel disease, or IBD. Accurate diagnosis is key to guiding therapy for patients, who might be as young as 2 years of age.
Patients with dementia with Lewy bodies (DLB) may have Alzheimers disease (AD) pathology that can be detected by plasma biomarkers. Our objective was to evaluate plasma biomarkers of AD and their association with positron emission tomography (PET) biomarkers of amyloid and tau deposition in the continuum of DLB, starting from prodromal stages of the disease.
Depending on the types of specimens that are referred to the outreach laboratory, there may be an opportunity to share a customer performance update report with the client so that they can align with, or even develop their own laboratory continuous improvement initiatives. This data-sharing provides valuable metrics and allows the client an opportunity to improve their services. Through identifying issues and working together to resolve them, the customer and the laboratory are aligned in their mission of putting the needs of the patient first.
In this episode of “Lab Medicine Rounds,” host Justin Kreuter, M.D., speaks with Alfredo Quinones-Hinjosa, M.D., a neurosurgeon and scientist at Mayo Clinic. From humble beginnings as a migrant worker, his story is one of resilience, determination, and a relentless pursuit of knowledge.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss current activity of infectious diseases.
PACE/State of FL - Presentation Recording Coming Soon - Sudden cardiac death (SCD) is a devastating event that occurs unexpectedly, often without any prior symptoms. This webinar will discuss how postmortem genetic testing may be used in conjunction with a traditional autopsy to assist with establishing cause and manner of death.
Robin Huiras-Carlson's connection with Mayo Clinic traces back to her early years, marked by a diagnosis of a rare genetic condition at the age of 10. Today, as a senior marketing specialist with Mayo Clinic Laboratories, she draws inspiration and purpose from this personal journey to illuminate Mayo’s positive impact on patients and ongoing evolution in diagnostics.
A winter storm is occurring in the Northeast which may impact specimen transport. The winter storm is expected to spread snow, strong winds, and create possible blizzard conditions which could impact courier pickups and route delays. We are monitoring the situation and will implement contingency plans as needed to avoid any potential delays. Clients should expect to be contacted directly by the couriers should any routes be modified or canceled.
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.
This week's research roundup feature: VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome, caused by somatic mutations in UBA1, is an autoinflammatory disorder with diverse systemic manifestations. Thrombosis is a prominent clinical feature of VEXAS. The risks factors and frequency of thrombosis in VEXAS are not well described, due to the disease's new discovery and paucity of large databases. We evaluated 119 VEXAS patients for venous and arterial thrombosis and correlated their presence with clinical outcomes and survival.
Prevented from providing testing services to its community members due to a non-compete agreement with a national laboratory, Kootenai Health laboratory leaders deepened their relationship with Mayo Clinic Laboratories, receiving tactical support and guidance to launch an in-house reference lab just days after the non-compete agreement expired.